GC Cell is a South Korean biotechnology company specialising in fully integrated cell and gene therapy development, manufacturing (CDMO), and bio-logistics services.

GC Cell operates from its headquarters in Yongin‑si, Gyeonggi‑do, South Korea, with a mission to “connect science to hope” by fast‑tracking innovation in cell and gene therapies. The company brings over 17 years of R&D and commercial experience in autologous and allogeneic cell therapies, including CAR‑NK, CAR‑T, CIK, and stem‑cell platforms. Its expertise spans from early-stage pipeline development to GMP-level commercial manufacturing. GC Cell also provides cell banking, cold-chain logistics, and analytical services, delivering an end-to-end CDMO solution from vein-to-vein GC Cell.

Key Products & Services

Cell & Gene Therapy CDMO

End-to-end contract manufacturing for cell and gene therapies

Over 72,400 commercial batches and 10,000 personalised cell therapy doses delivered

Global tech transfer capabilities across Asia and the US

Pipeline Cell Therapy Products

Immuncell‑LC (GCC4002): Adjuvant NK/CIK therapy for liver cancer, with ongoing Phase 3 or approved status in Korea

CAR‑NK products: GCC4001 (CD19), GCC2003 (HER2), GCC2005 (CD5 – T‑cell lymphoma), among others

Bio‑Logistics & Cell Banking

Cold‑chain end-to-end delivery for clinical and commercial products

Umbilical cord blood banking with rigorous QC and long‑term viability testing

Analytical & Laboratory Services

GMP‑grade quality analysis, process development, and regulatory documentation support

With comprehensive CDMO capabilities—spanning R&D, GMP manufacturing, logistics, and advanced therapies—GC Cell positions itself as a global innovator in cell and gene therapy. Its strong pipeline and robust infrastructure offer a powerful platform for both client collaborations and proprietary clinical advancement.